NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$6.18

21 Sep
2021

0.050

OPEN

$6.03

0.82%

HIGH

$6.22

884,200

LOW

$6.01

TARGET
$6.22 0.6% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 2.9 4.4 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx - 15.7% 54.4% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 141.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 0.0% 0.0% xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx101.8 M
Book Value Per Share xxxxxxxxxxxxxxx45.0
Net Operating Cash Flow xxxxxxxxxxxxxxx7.3 M
Net Profit Margin xxxxxxxxxxxxxxx8.42 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx5.48 %
Return on Equity xxxxxxxxxxxxxxx6.60 %
Return on Total Capital xxxxxxxxxxxxxxx6.33 %
Capex xxxxxxxxxxxxxxx1.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.36 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx6.1 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

25/08/2021

3

Hold

$6.40

3.56%

Nanosonic's FY21 result outpaced Ord Minnett's forecast, thanks to an uptick in revenue.

Capital devices and consumables sales posted a strong recovery as the operating environment normalised and the announcement of the Coris platform pleased the broker.

Lower-than-expected operating expenses supported an 86% beat on the profit line but the company provides higher than expected cost guidance for FY22.

Target price rises to $6.40 from $5.40. Hold rating retained.

FORECAST
Ord Minnett forecasts a full year FY22 dividend of 0.00 cents and EPS of 4.00 cents.
Ord Minnett forecasts a full year FY23 dividend of 0.00 cents and EPS of 7.00 cents.

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

NAN STOCK CHART